Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17667933 | 0.91 | PTGDR2 (0.44) | MAPTPOLBGAAPTGDR2SMN1; SMN2 | |
| SCHEMBL3746367 | 0.87 | POLB (0.42) | MAPTPOLBRAB9AGAASMN1; SMN2 | |
| SCHEMBL2367664 | 0.86 | MAPT (0.48) | MAPTPOLBRAB9AGAAPTGDR2 | |
| SCHEMBL1923550 | 0.85 | KDM4E (0.49) | MAPTPOLBPTGDR2KCNH2MEN1 | |
| SCHEMBL2367584 | 0.83 | MAPT (0.54) | MAPTPOLBGAASMN1; SMN2PLA2G1B | |
| SCHEMBL2367982 | 0.83 | HSD17B10 (0.54) | MAPTPOLBPTGDR2SMN1; SMN2MEN1 | |
| SCHEMBL2367582 | 0.83 | KCNH2 (0.48) | MAPTPOLBPTGDR2SMN1; SMN2KCNH2 | |
| SCHEMBL3763320 | 0.82 | GRM5 (0.44) | MAPTPOLBGAASMN1; SMN2CYP1A2 | |
| SCHEMBL1923628 | 0.82 | SMN1; SMN2 (0.52) | MAPTPOLBRAB9AGAAPTGDR2 | |
| SCHEMBL3651954 | 0.81 | POLB (0.41) | MAPTPOLBRAB9AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207774-B1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-13 | — | — | EP | claimed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | claimed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | claimed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | claimed |
| EP-2207774-B1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2207774-B1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| WO-2009060054-A1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297097-A1 | COMPOUNDS | APP, BACE1, SCD | MAPT 67/4885POLB 2392/4885RAB9A 4100/4885 |
| US-20120225878-A1 | COMPOUNDS | CYP11B2, CYP11B1, SCD | MAPT 3973/4885POLB 2693/4885RAB9A 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.